Biostate AI, a Palo Alto, California-based scalable biodata foundry company, has raised $4 million in funding. Matter Venture Partners led the investment, with participation from Vision Plus Capital, Catapult VC, the Caltech Seed Fund, Dario Amodei, CEO of Anthropic, Joris Poort, CEO of Rescale, Michael Schnall-Levin, CTO of 10X Genomics, and Emily Leproust, CEO of Twist Bioscience.
The monies will be used to grow the company’s operations and development initiatives.
Biostate AI, led by CEO David Zhang, is a firm created in 2023 with the goal of producing generative AI that will help all aspects of human health.
Total RNA sequencing employs patent-pending Barcode-Integrated Reverse Transcription (BIRT) technology to examine all types of RNA, including long non-coding RNAs (lncRNAs), microRNAs (miRNAs), circular RNAs (circRNAs), and enhancer RNAs (eRNAs).
In addition, the business released OmicsWeb Copilot, a conversational AI designed to assist scientists with data analysis and visualization. Copilot uses large-language models (LLMs) to interpret user requests and intent in order to create custom software and scripts for data analysis. In addition to evaluating the user’s own uploaded data, it gives access to over 1000 distinct RNAseq datasets curated by the Biostate team.
Biostate AI, with headquarters and laboratories in Palo Alto, CA and Houston, TX, works with academic, nonprofit, and business partners to build technology and collect multiomic biodata.
David Zhang commented on the development, saying: “Biostate AI has created instrumental technologies to simplify the collecting of more biological data at cheaper prices. We are delighted to provide these skills to our academic and industrial colleagues and collaborators.”
